Psoriasis: An autoimmune disorder

  • Purnima Tripathi Institute of Pharmacy, Bundelkhand University, Jhansi, 284128, U.P., India
  • Peeyush Bhardwaj Institute of Pharmacy, Bundelkhand University, Jhansi, 284128, U.P., India

Abstract

Psoriasis is an auto-immune disorder of the skin. It is characterized by the hyperproliferation of keratinocytes.  Severity of the disease depends on the body area affected. Both genetic as well as environmental factors are responsible for it. It affects around 2-3% of world’s population. Psoriasis not only causes physical problems, it also affects mental and social well being of the patient. It may also lead to some Comorbidities like heart problems, diabetes, psychological problems, Crohn’s disease , etc.  Keeping in view the impact it creats in the patient’s life, steps should be taken to create awareness of psoriasis. This article attempts to provide a comprehensive view on the psoriasis. It includes the various forms of psoriasis with their specific features, causes of psoriasis, diagnosis and assessment tools used, treatments available for its management including topical as well as systemic therapy and associated problems.


Keywords: Plaque, Psoriasis, Pustules

Keywords: Plaque, Psoriasis, Pustules

Downloads

Download data is not yet available.

Author Biographies

Purnima Tripathi, Institute of Pharmacy, Bundelkhand University, Jhansi, 284128, U.P., India

Institute of Pharmacy, Bundelkhand University, Jhansi, 284128, U.P., India

Peeyush Bhardwaj, Institute of Pharmacy, Bundelkhand University, Jhansi, 284128, U.P., India

Institute of Pharmacy, Bundelkhand University, Jhansi, 284128, U.P., India

References

1. Willan R, “On Cutaneous Diseases” London: Johnson; 1808
2. Nestle FO, Kaplan DH, Barker J, “Psoriasis” N. Engl. J. Med, 2009; 361:496–509
3. Zangeneh FZ, Shooshtary FS, “Psoriasis — Types, Causes and Medication” http://dx.doi.org/10.5772/54728
4. Christophers E, “Psoriasis—epidemiology and clinical spectrum” Clin Exp Dermatol, 2001; 26:314–20.
5. Wolf-Henning Boehncke, Michael P Schön, “Psoriasis” Lancet, 2015; 386:983–94
6. aNaldi L, “Epidemiology of psoriasis” Curr Drug Targets Inflamm Allergy, 2004; 3:121–128.
7. aGriffiths CE, Barker JN, “Pathogenesis and clinical features of psoriasis” Lancet, 2007; 370(9583):263-71.
8. bGriffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne JP, Fry L, “A classification of psoriasis vulgaris according to phenotype” Br J Dermatol, 2007; 156: 258-62.
9. Henseler T, Christophers E, “Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris” J Am Acad Dermatol, 1985; 13:450–6.
10. Goodfield M, Hull SM, Holland D, Roberts G, Wood E, Reid S, Cunliffe W, “Investigations of the ‘active’ edge of plaque psoriasis: vascular proliferation precedes changes in epidermal keratin” Br J Dermatol, 1994; 131:808–13.
11. bNaldi L, Colombo P, Benedetti EP, Piccitto R, Chatenoud L, La Vecchia C, “Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population” Dermatology, 2004; 208:38–42.
12. bGriffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne JP, Fry L, “A classification of psoriasis vulgaris according to phenotype” Br J Dermatol, 2007; 156:258-62.
13. Beylot C, “Clinical aspects of psoriasis” Rev Prat, 2004; 54:19–27.
14. Melski JW, Bernhard JD, Stern RS, “The Koebner (isomorphic) response in psoriasis: associations with early age of onset and multiple previous therapies” Arch Dermatol, 1983; 119:655–659.
15. Zanchi M, Favot F, Bizzarini M, Piai M, Donini M, Sedona P, “Botulinum toxin type-A for the treatment of inverse psoriasis” J Eur Acad Dermatol Venereol, 2008; 22:431-6.
16. Telfer NR, Chalmers RJ, Whale K, Colman G, “The role of streptococcal infection in the initiation of guttate psoriasis” Arch Dermatol, 1992; 128:39-42.
17. Naldi L, Peli L, Parazzini F, Carrel CF, “Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study" J Am Acad Dermatol, 2001; 44:433–438.
18. Asumalahti K, Ameen, Suomela S, Hagforsen E, Michaëlsson G, Evans J, Munro M, Veal C, Allen M, Leman J, Burden AD, Kirby B, Connolly M, Griffiths CEM,Trembath RC, Kere G, Kere SU, Barker J NWN, “Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis” J Invest Dermatol, 2003; 120:627–632.
19. Mallon E, Bunce M, Savoie H, Rowe A, Newson R, Gotch F, Bunker CB, “HLA-C and guttate psoriasis” Br J Dermatol, 2000; 143:1177-82.
20. Zelickson BD, Muller SA, “Generalised pustular psoriasis. A review of 63 cases” Arch Dermatol, 1991; 127:1339–1345.
21. Viguier M, Allez M, Zagdanski AM, “High frequency of cholestasis in generalized pustular psoriasis. Evidence for neutrophilic involvement of the biliary tract” Hepatology, 2004; 40:452–458.
22. Roelandts R, “The history of phototherapy: something new under the sun?” J Am Acad Dermatol, 2002; 46:926-30.
23. O'Doherty CJ, MacIntyre C, “Palmoplantar pustulosis and smoking” 1985; 291:861–864.
24. Balasubramaniam P, Berth-Jones J. Erythroderma: 90% skin failure. Hosp Med, 2004; 65:100–102.
25. Kahl C, Hansen B, Reich K, “Nail psoriasis--an ignored disorder Pathogenesis, diagnosis and therapy” Hautarzt, 2012; 63:184-91.
26. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003; 7:317–321.
27. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, Stern RS, Feldman SR, Rolstad T, “Epidemiology of psoriatic arthritis in the population of the United States” J Am Acad Dermatol, 2005; 53:573.
28. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM, “Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population based study” Arthritis Rheum, 2009; 6:233–239.
29. Gaydukova I, Rebrov A, Nikitina N, Poddubnyy D, “Decreased heart rate variability in patients with psoriatic arthritis” Clin Rheumato, 2012 Jun 7 (Epub ahead of print)
30. Kane D, Stafford L, Bresnihan B, FitzGerald O, “A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience” Rheumatology, (Oxford). 2003; 42:1460-8.
31. Baran R, “The burden of nail psoriasis: an introduction” Dermatology, 2010; 221 Suppl 1:1-5.
32. Rahimi H, Ritchlin CT, “Altered bone biology in psoriatic arthritis” Curr Rheumatol, Rep. 2012; 14:349-57.
33. British association of dermatologists patient information leaflet, psoriasis – an overview, updated October 2018 review, Lay review date October 2018.
34. Angelo Valerio Marzano, Federica Derlino, Emilio Francesco Berti, “Dermatopathology” 2018; 5:14–15, DOI: 10.1159/000486304
35. Christophers E, Metzler G, Röcken M, “Bimodal immune activation in psoriasis” Br J Dermatol, 2014; 170:59–65.
36. Kastner DL, Aksentijevich I, Goldbach-Mansky R, “Autoinflammatory disease reloaded: a clinical perspective” Cell, 2010; 140:784–790.
37. Agnieszka Bożek, Adam Reich, “The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment” Adv Clin Exp Med, 2017; 26(5):851–856
38. Fredriksson T, Pettersson U. Oral treatment of pustulosis pal¬mo-plantaris with a new retinoid, Ro 10-9359. Dermatologica. 1979; 158:60–64.
39. Berth-Jones J, Grotzinger K, Rainville C, et al. A study examining inter- and intrarater reliability of three scales for measuring sever-ity of psoriasis: Psoriasis area and severity index, physician glob-al assessment and lattice system physician global assessment. Br J Dermatol. 2006; 155:707–713.
40. Robinson A, Kardos M, Kimball AB, “Physician global assessment (PGA) and psoriasis area and severity index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis” J Am Acad Derma-tol, 2012; 66:369–375.
41. Feldman S, Krueger G, “Psoriasis assessment tools in clinical trials” Ann Rheum Dis., 2005; 64(Suppl 2):65–68.
42. Spuls PI, Lecluse LL, Poulsen ML, Bos JD, Stern RS, Nijsten T, “How good are clinical severity and outcome measures for psoriasis?: Quantitative evaluation in a systematic review” J Invest Dermato, 2010; 130:933–943.
43. Malcolm W. Greaves, Gerald D. Weinstein, “Treatment of Psoriasis” Drug Therapy, Vol. 332 No. 9
44. Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr, “Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris” J Am Acad Dermatol, 1986; 15:504-7.
45. Ghadially R, Halkier-Sorensen L, Elias PM, “Effects of petrolatum on stratum
corneum structure and function” J Am Acad Dermatol, 1992; 26:387-96.
46. Young E, “The external treatment of psoriasis: a controlled investigation of the effects of coal tar” Br J Dermatol, 1970; 82:510-5.
47. Perry HO, Soderstrom CW, Schulze RW, “The Goeckerman treatment of psoriasis” Arch Dermatol, 1968; 98:178-82.
48. Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O’Brien PC, “Skin cancer in patients with psoriasis treated with coal tar: a 25-year follow-up study” Arch Dermatol, 1981; 117:465-8.
49. Ingram JT, “The approach to psoriasis” BMJ, 1953; 2:591-4.
50. MacLennan A, Hellier FF, “The treatment time in psoriasis” Br J Dermatol, 1961; 73:439-44.
51. Ashton RE, Andre P, Lowe NJ, Whitefield M, “Anthralin: historical and current
Perspectives” J Am Acad Dermatol, 1983; 9:173-92.
52. Finnen MJ, Lawrence CM, Shuster S, “Inhibition of dithranol inflammation by free-radical scavengers” Lancet, 1984; 2:1129-30.
53. Schaefer H, Farber EM, Goldberg L, Schalla W, “Limited application period for dithranol in psoriasis: preliminary report on penetration and clinical efficacy” Br J Dermatol, 1989; 102:571-3.
54. Lowe NJ, Ashton RE, Koudsi H, Verschoore M, Schaefer H, “Anthralin for psoriasis: short-contact anthralin therapy compared with topical steroid and conventional anthralin” J Am Acad Dermatol, 1984; 10:69-72.
55. Liem WH, McCullough JL, Weinstein GD, “Is topical therapy effective for psoriasis: results of survey of U.S. dermatologists” J Invest Dermatol, 1992; 98:602. abstract.
56. Lane AT, Wachs GN, Weston WL, “Once-daily treatment of psoriasis with glucocorticosteroid ointments” J Am Acad Dermatol,1983; 8:523-5.
57. Du Vivier A, “Tachyphylaxis to topically applied steroids” Arch Dermatol, 1976; 112:1245-8.
58. Baker H, Ryan TJ, “Generalised pustular psoriasis: a clinical and epidemiological study of 104 case” Br J Dermatol, 1968; 80:771-93.
59. James VH, Munro DD, Feiwel M, “Pituitary-adrenal function after occlusive topical therapy with betamethasone-17-valerate” Lancet, 1967; 2:1059-61.
60. Turpeinen M, “Absorption of hydrocortisone from the skin reservoir in atopic dermatitis” Br J Dermatol, 1991;124:358-60
61. Morimoto S, Yoshikawa K, Kozuka T, et al., “An open study of vitamin D3 treatment in psoriasis vulgaris” Br J Dermatol, 1986; 115:421-9.
62. Kragballe K, “Treatment of psoriasis by the topical application of the novel cholecalciferol analogue calcipotriol (MC 903)” Arch Dermatol, 1989; 125: 1647-52.
63. Kragballe K, Gjertsen BT, De Hoop D, et al, “Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris” Lancet, 1991; 337:193-6. [Erratum, Lancet 1991;337:988.]
64. Dwyer C, Chapman RS, “Calcipotriol and hypercalcaemia” Lancet, 1991; 338: 764-5.
65. Stern RS, Armstrong RB, Anderson TF, et al., “Effect of continued ultraviolet B phototherapy on the duration of remission of psoriasis: a randomized study” J Am Acad Dermatol, 1986; 15:546-52.
66. Stern RS, Zierler S, Parrish JA, “Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation” Lancet, 1980; 1:732-5.
67. Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL, “Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial” J Invest Dermatol, 1977; 68:328-35.
68. Pathak MA, Fitzpatrick TB, Parrish JA, “Pharmacologic and molecular aspects of psoralen Photochemotherapy” In: Farber E, Cox AJ, Jacobs PH, Nall ML, eds. Psoriasis: proceedings of the second international symposium, New York: Yorke Medical Books, 1977:262-71.
69. Kripke ML, Morison WL, Parrish JA, “Systemic suppression of contact hypersensitivity
in mice by psoralen plus UVA radiation (PUVA)” J Invest Dermatol, 1983; 81:87-92.
70. Stern RS, Fitzpatrick TB, Parrish JA, Honigsmann H, Wolff K, “Oral psoralen Photochemotherapy” In: Roenigk HH Jr, Maibach HI, eds. Psoriasis, 2nd ed. New York: Marcel Dekker, 1991:603-23.
71. Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL, “Cutaneous squamous-cell carcinoma in patients treated with PUVA” N Engl J Med, 1984; 310:1156-61.
72. Stern RS, “Genital tumors among men with psoriasis exposed to psoralens and ultraviolet A radiation (PUVA) and ultraviolet B radiation” N Engl J Med, 1990; 322:1093-7.
73. Stern RS, Lange R, “Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment” J Invest Dermatol, 1988;91: 120-4. [Erratum, J Invest Dermatol 1989; 92:300.]
74. Fritsch PO, Honigsmann H, Jaschke E, Wolff K, “Augmentation of oral methoxsalen photochemotherapy with an oral retinoic acid derivative” J Invest Dermatol, 1978; 70:170-82.
75. Fischer T, “Topical PUVA and bath PUVA” In Roenigk HH Jr, Maibach HI, eds. Psoriasis, 2nd ed. New York: Marcel Dekker, 1991:633-44.
76. McCullough JL, Weinstein G,” The action of cytotoxic drugs on cell proliferation in psoriasis” In: Wright NA, Camplejohn RS, eds. Psoriasis: cell
Proliferation, Edinburgh, Scotland: Churchill Livingstone, 1983:347-54.
77. Weinstein GD, Jeffes E, McCullough JL, “Cytotoxic and immunologic effects of methotrexate in psoriasis” J Invest Dermatol, 1990; 95:Suppl:49S-52S.
78. Weinstein GD, McCullough JL, Ross PA, “Cell kinetic basis for pathophysiology of psoriasis” J Invest Dermatol, 1985; 85:579-83.
79. Weinstein GD, Frost P, ‘Methotrexate for psoriasis: a new therapeutic schedule,”Arch Dermatol, 1971;103:33-8.
80. Peckham PE, Weinstein GD, McCullough JL, “The treatment of severe psoriasis: a national survey” Arch Dermatol, 1987; 123:1303-7.
81. Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD, “Methotrexate in psoriasis: revised guidelines” J Am Acad Dermatol, 1988; 19:145-56.
82. Weinstein G, Roenigk H, Maibach H, et al., “Psoriasis-liver-methotrexate interactions” Arch Dermatol, 1973;108:36-42.
83. Van Ness MM, Diehl AM, “Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes?” Ann Intern Med, 1989; 111:473-8.
84. Zachariae H, “Methotrexate side-effects” Br J Dermatol, 1990; 122:Suppl 36: 127-33.
85. Stadler R, “Three generations of retinoids: basic pharmacological data, mode of action and effects on keratinocyte proliferation and differentiation” In:Greaves MW, Shuster S, eds. Pharmacology of the skin. Vol. 2. Berlin, Germany: Springer-Verlag, 1990:329-58.
86. Elder JT, Fisher GJ, Zhang QY, et al., “Retinoic acid receptor gene expression in human skin” J Invest Dermatol, 1991; 96:425-33.
87. Ellis CN, Hermann RC, Gorsulowsky DC, Goldfarb MT, Voorhees JJ, “Etretinate therapy reduces inpatient treatment of psoriasis” J Am Acad Dermatol, 1987; 17:787-91.
88. Gollnick HPM, Orfanos CE, “Clinical efficacy of etretinate and acitretin: European Experience” In: Roenigk HH Jr, Maibach HI, eds. Psoriasis. 2nd ed. New York: Marcel Dekker, 1991:725-48.
89. Moy RL, Kingston TP, Lowe NJ, “Isotretinoin vs etretinate therapy in generalized pustular and chronic psoriasis” Arch Dermatol, 1985; 121:1297-301.
90. Orfanos CE, Runne U, “Systemic use of a new retinoid with and without local dithranol treatment in generalized psoriasis” Br J Dermatol, 1976; 95:101-3.
91. Parker S, Coburn P, Lawrence C, Marks J, Shuster S “A randomized doubleblind comparison of PUVA-etretinate and PUVA-placebo in the treatment of chronic plaque psoriasis” Br J Dermatol, 1984; 110:215-20.
92. Saurat JH, Geiger JM, Amblard P, et al., “Randomized double-blind multicenter study comparing acitretin-PUVA, etretinate-PUVA and placebo-PUVA in the treatment of severe psoriasis” Dermatologica, 1988; 177:218-24.
93. Larsen FG, Jakobsen P, Knudsen J, Weismann K, Kragballe K, Nielsen- Kudsk F, “Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol” J Invest Dermatol, 1993; 100:623-7.
94. DiGiovanna JJ, Helfgott RK, Gerber LH, Peck GL, “Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate” N Engl J Med, 1986; 315:1177-82.
95. Ellis CN, Fradin MS, Messana JM, et al., “Cyclosporine for plaque-type psoriasis: results of a multidose, double-blind trial” N Engl J Med, 1991; 324:277-84.
96. Wong RL, Winslow CM, Cooper KD, “The mechanism of action of cyclosporine A in the treatment of psoriasis” Immunol Today, 1993; 14:69-74.
97. O’Keefe SJ, Tamura J, Kincaid RL, Tocci MJ, O’Neill EA, “FK-506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin” Nature, 1992; 357:692-4.
98. Gupta AK, Rocher LL, Schmaltz SP, et al., “Short-term changes in renal function, blood pressure, and electrolyte levels in patients receiving cyclosporine for dermatologic disorders” Arch Intern Med, 1991; 151:356-62.
99. Korstanje MJ, Bilo HJG, Stoof TJ, “Sustained renal function loss in psoriasis patients after withdrawal of low-dose cyclosporin therapy” Br J Dermatol, 1992; 127:501-4.
100. Mihatsch MJ, Wolff K, “Consensus conference on cyclosporin A for psoriasis” Br J Dermatol, 1992; 126:621-3.
101. AB Kimball, U Gieler, D Linder, F Sampogna, RB Warren, M Augustin, “Psoriasis: is the impairment to a patient’s life cumulative?” JEADV 2010; 24:89–1004, DOI: 10.1111/j.1468-3083.2010.03705.x
102. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, “The risk of lymphoma in patients with psoriasis “ J Invest Dermatol, 2006; 126:2194–201.
103. Lindelof B, Eklund G, Liden S, Stern RS “The prevalence of malignant tumors in patients with psoriasis” J Am Acad Dermatol, 1990; 22:1056–60.
104. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB “Risk of myocardial infarction in patients with psoriasis” JAMA, 2006; 296:1735–41.
105. Mallbris L, Akre O, Granath F, et al “Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients” Eur J Epidemiol, 2004; 19:225–30.
106. Mrowietz U, Elder JT, Barker J, “The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients” Arch Dermatol Res, 2006; 298:309–18.
Statistics
5 Views | 4 Downloads
How to Cite
1.
Tripathi P, Bhardwaj P. Psoriasis: An autoimmune disorder. JDDT [Internet]. 15Sep.2020 [cited 25Sep.2020];10(5):316-24. Available from: http://jddtonline.info/index.php/jddt/article/view/4327